TABLE 7

Baseline polymorphisms and treatment-emergent substitutions in 18 GT3-infected patients experiencing virologic failure

Prior treatment experience and durationaPatient no.Cirrhosis (Y/N)dOutcomeeVariant(s) by time point (prevalence [%] within patient's viral population)g
NS3NS5A
BaselineTime of VFfPosttreatment wk 24BaselineTime of VFPosttreatment wk 24
TN
    8 wk1bNBTA166S (60.6), Q168R (61.4)Q80R (59.2), A156G (99.6)A166S (85.4), Q168R (85.6)A30K (99.6)A30K (99.9), Y93H (99.7)A30K (99.8), Y93H (99.1)
2NRA166S (52.4)Y56H (88.5), Q168L (95.5)Q168L (99.3)A30K (99.8)A30K (99.8), Y93H (99.8)A30K (99.8), Y93H (99.6)
3NRT54S (98.4)T54S (99.4)T54S (99.7)NoneNoneNone
4NRA166S (99.2)A166S (97.7)A166S (99.9)NoneY93H (99.6)Y93H (99.6)
5NRNoneY56H (99.5)NoneA30K (99.8)A30K (99.8), Y93H (99.6)A30K (99.9)
6NRNoneQ168L (98.9)NoneA30K (99.7)A30K (99.8), Y93H (99.7)A30K (99.9), Y93H (77.1)
    12 wk7NBTQ168R (28.5)Y56H (98.5), Q168R (99.2)NoneA30K (16.3), A30V (39.2), Y93H (37.2)A30K (99.9), Y93H (99.8)A30K (99.8), Y93H (19.6)
8NRNoneNoneNoneNoneA30G (32.8), Y93H (99.9)L31F (33.2), Y93H (99.5)
9cNRNoneQ80K (99.0)Q80K (99.4)V31M (99.8)V31M (99.8), Y93H (99.8)V31M (99.9), Y93H (99.9)
TE-PRS
    12 wk10bNRNoneY56H (90.8), Q168R (83.6)NoneA30K (99.8)A30K (99.9), Y93H (99.5)A30K (99.8)
11NBTA166S (97.0)Y56H (95.5), A166S (98.3), Q168L (69.0)A166S (99.8)A30K (99.7)A30K (99.8), Y93H (99.5)A30K (99.8)
12NRNoneNoneNAY93H (38.7)L31F (38.9), Y93H (99.3)Y93H (99.8)
13NRNoneNoneNoneA30K (99.6)A30K (99.8), Y93H (99.6)A30K (99.8), Y93H (99.3)
14NRNoneNoneNoneY93H (99.3)Y93H (99.6)Y93H (99.8)
    16 wk15YRA166S (95.1)NoneNANoneM28G (97.5)NA
16NRNoneY56H (99.4), Q168R (99.8)NoneA30K (99.8)A30K (99.9), Y93H (99.9)A30K (99.8), Y93H (81.2)
17YRNoneNoneNoneNoneL31F (99.7), Y93H (99.8)L31F (30.7), Y93H (99.6)
18bYBTA166S (99.0)A156G (99.3), A166S (99.2)A166S (99.8)NoneA30K (99.8), Y93H (99.7)A30K (99.9), Y93H (98.9)
  • a TN, treatment-naive; TE-PRS, treatment-experienced to peg-IFN plus RBV with or without sofosbuvir. Seventeen patients were infected with GT3a, and one was infected with GT3b, as indicated.

  • b Patient had not been adherent to treatment regimen.

  • c Patient was infected with GT3b.

  • d Y, yes; N, no.

  • e BT, breakthrough; R, relapse.

  • f VF, virologic failure.

  • g Variants at amino acid positions 36, 43, 54, 55, 56, 80, 155, 156, 166, and 168 in NS3 or 24, 28, 30, 31, 32, 58, 92, and 93 in NS5A, relative to subtype-specific reference sequences at a 15% detection threshold are listed. None, a polymorphism or substitution at one of at the above-listed amino acid positions was not detected; NA, not available.